Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 8 of 31 for:    rhBMP-2 | Industry

Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: September 12, 2008
Last updated: June 15, 2015
Last verified: June 2015
The main purpose of this study is to assess whether a locally-administered rhBMP-2/CPM injection can rapidly increase bone mass in subjects at high risk for osteoporotic fractures of the hip. All subjects will receive standard treatment for low bone mass, consisting of bisphosphonates, calcium, and vitamin D (all taken by mouth). Subjects that are randomly selected to receive treatment with rhBMP-2 will receive an injection directly into the hip. The injection is given in a surgery room using a light anesthesia.

Condition Intervention Phase
Drug: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Drug: bisphosphonates, calcium, and vitamin D
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Randomized, Active-controlled, Parallel-group, Dose-finding And Safety Study Of Recombinant Human Bone Morphogenetic Protein-2 (Rhbmp-2)/Calcium Phosphate Matrix (Cpm) In Subjects With Decreased Bone Mineral Density

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Changes in Bone Mineral Density will be measured by dual-energy x-ray absorptiometry [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • Safety of injecting rhBMP-2/CPM, measured by physical exams and other tests such as radiographs and electrocardiograms. [ Time Frame: 36 months ]
  • Feasibility of administering rhBMP-2/CPM as a minimally invasive technique in an outpatient (ambulatory care) setting. [ Time Frame: Dosing ]
  • Evaluate long-term changes in BMD after injection of rhBMP-2/CPM. [ Time Frame: 36 Months ]
  • Evaluate bone quality with emphasis on cortical thickness and trabecular volume in region(s) of interest, utilizing quantitative computed tomography. [ Time Frame: 24 Months ]
  • Evaluate changes in biochemical markers of bone turnover to identify markers that are predictive of changes in BMD from baseline. [ Time Frame: 12 Months ]

Enrollment: 50
Study Start Date: December 2008
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
rhBMP-2/CPM , 1.0 mg/mL
Drug: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
Experimental: 2
rhBMP-2/CPM , 2.0 mg/mL
Drug: rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)
Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
Active Comparator: 3
Oral bisphosphonate therapy (standard of care)
Drug: bisphosphonates, calcium, and vitamin D
Oral bisphosphonate therapy


Ages Eligible for Study:   65 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Community-dwelling, ambulatory (with or without assistive device), postmenopausal females, age greater than 65 years.
  • BMD T-score (total hip or femoral neck) of -2.5 or less in at least 1 hip. Subjects with BMD T-scores of -2.0 or less may be enrolled if at least one of the following risk factors is also present:
  • Age greater than 75 years
  • Family (maternal) history of fragility fracture
  • Previous fragility fracture (self) after age 45
  • Subjects may either be treatment naïve or on a previously-established regimen ( greater than 1year, but less than 5 years duration) of bisphosphonate therapy. Subjects must be willing to comply with 1of the 3 protocol-designated oral bisphosphonates (risedronate, alendronate, or ibandronate sodium) with risedronate considered as first-line therapy.

Exclusion Criteria:

  • Metabolic bone disorder or disease affecting bone and mineral metabolism (eg, Paget's disease, vitamin D deficiency [ less than 20 ng/mL], hyperparathyroidism, renal osteodystrophy, osteomalacia, hypocalcemia, hypercalcemia).
  • Coagulopathy and/or history of venous thromboembolic events (deep vein thrombosis, pulmonary embolus, retinal vein thrombosis) within the past 12 months.
  • Inflammatory arthritis including rheumatoid, psoriatic, or crystal-induced (gouty) arthritis, or those associated with systemic lupus erythematosus (SLE), spondyloarthropathy, Reiters syndrome, or Crohns disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00752557

  Show 35 Study Locations
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00752557     History of Changes
Other Study ID Numbers: 3100N0-2213
B1921002 ( Other Identifier: Alias Study Number )
2007-007456-34 ( EudraCT Number )
Study First Received: September 12, 2008
Last Updated: June 15, 2015

Keywords provided by Pfizer:
Bone mineral density
bone morphogenetic protein

Additional relevant MeSH terms:
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Vitamin D
Calcium, Dietary
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on April 25, 2017